Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	2,163	2,081	1,009	2,995	6,806	3,493
Market Cap Growth	202.12%	106.29%	-66.33%	-55.99%	94.85%	220.45%
Enterprise Value	1,885	1,810	616	2,556	6,223	3,192
PE Ratio	-	-4.69	-2.55	-8.75	-26.22	-17.68
PS Ratio	1136.09	1749.89	-	-	-	-
PB Ratio	3.18	3.56	2.02	4.82	10.37	11.68
P/FCF Ratio	-10.22	-5.42	-3.22	-11.28	-27.02	-21.07
P/OCF Ratio	-10.77	-5.75	-3.45	-13.14	-33.18	-21.98
EV/Sales Ratio	989.94	1522.44	-	-	-	-
EV/EBITDA Ratio	-9.25	-4.37	-1.64	-7.79	-24.81	-16.85
EV/EBIT Ratio	-8.49	-4.04	-1.56	-7.47	-23.97	-16.16
EV/FCF Ratio	-9.53	-4.71	-1.97	-9.63	-24.70	-19.25
Debt / Equity Ratio	0.12	0.13	0.17	0.12	0.08	0.04
Debt / EBITDA Ratio	-0.20	-0.18	-0.23	-0.22	-0.21	-0.06
Debt / FCF Ratio	-0.21	-0.20	-0.27	-0.27	-0.21	-0.07
Quick Ratio	4.36	3.14	5.23	5.72	11.57	8.00
Current Ratio	4.63	2.79	5.24	5.70	11.59	8.10
Asset Turnover	0.00	0.00	0	0	0	0
Return on Equity (ROE)	-71.50%	-70.90%	-82.60%	-50.50%	-43.80%	-53.20%
Return on Assets (ROA)	-55.20%	-55.30%	-62.80%	-42.70%	-39.10%	-48.20%
Return on Capital (ROIC)	-61.15%	-69.73%	-68.17%	-49.44%	-36.99%	-66.63%
Earnings Yield	-20.79%	-21.34%	-39.25%	-11.43%	-3.81%	-5.66%
FCF Yield	-18.73%	-18.46%	-31.05%	-8.86%	-3.70%	-4.75%
Buyback Yield / Dilution	-24.58%	-47.64%	-3.82%	-10.92%	-11.23%	-27.82%
Total Shareholder Return	-24.58%	-47.64%	-3.82%	-10.92%	-11.23%	-27.82%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).